Evidence map›Paper›PMID 40672687›Full record

ArticleACS pharmacology & translational science2025

Azathioprine Metabolites in Erythrocytes and DNA for Therapy Monitoring in Very Early Onset Inflammatory Bowel Disease Pediatric Patients.

Giulia Zudeh, Martina Franzin, Marianna Lucafò, Matteo Bramuzzo, Debora Curci, Jun J Yang, Maud Maillard, Giuliana Decorti, Gabriele Stocco

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giulia ZudehDepartment of Translational and Advanced Diagnostics, Institute for Maternal and Child Health I.R.C.C.S. Burlo Garofolo, Trieste 34137, Italy.ORCID https://orcid.org/0000-0001-6168-5662
Martina FranzinDepartment of Translational and Advanced Diagnostics, Institute for Maternal and Child Health I.R.C.C.S. Burlo Garofolo, Trieste 34137, Italy.
Marianna LucafòDepartment of Life Sciences, University of Trieste, 34128 Trieste, Italy.
Matteo BramuzzoDepartment of Gastroenterology, Digestive Endoscopy and Nutrition Unit, Institute for Maternal and Child Health I.R.C.C.S. Burlo Garofolo, Trieste 34137, Italy.
Debora CurciDepartment of Translational and Advanced Diagnostics, Institute for Maternal and Child Health I.R.C.C.S. Burlo Garofolo, Trieste 34137, Italy.
Jun J YangDepartment of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-3678, United States.
Maud MaillardDepartment of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-3678, United States.
Giuliana DecortiDepartment of Medical, Surgical and Health Sciences, University of Trieste, Trieste 34129, Italy.
Gabriele StoccoDepartment of Translational and Advanced Diagnostics, Institute for Maternal and Child Health I.R.C.C.S. Burlo Garofolo, Trieste 34137, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azathioprine is used for inflammatory bowel disease (IBD) therapy. Patients under 6 years of age (very early onset, VEO-IBD) showed distinctive clinical characteristics, such as increased activity of thiopurine-methyltransferase (TPMT), a crucial enzyme for thiopurine metabolism.

Indexed as

azathioprineDNA-TGpediatricpharmacogeneticsTGNvery early onset inflammatory bowel disease

Identifiers

PMID40672687
PMCPMC12260932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.